載入...
Primary resistance to osimertinib despite acquired T790M
Current National Comprehensive Cancer Network (NCCN) guidelines suggest plasma‐based testing (liquid biopsy) for T790M in epidermal growth factor receptor (EGFR)‐mutated non‐small cell lung carcinoma (NSCLC) with acquired resistance to first‐/second‐generation EGFR tyrosine kinase inhibitors (TKIs)....
Na minha lista:
| 發表在: | Respirol Case Rep |
|---|---|
| Main Authors: | , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
John Wiley & Sons, Ltd
2020
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7002899/ https://ncbi.nlm.nih.gov/pubmed/32042433 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/rcr2.532 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|